Rover 800 series

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on:

Donnerstag, November 9, 2023

Additionally, we look forward to progressing AVTX-008, our BTLA agonist fusion protein with high-binding affinity and serum stability, to IND.

Key Points:

Additionally, we look forward to progressing AVTX-008, our BTLA agonist fusion protein with high-binding affinity and serum stability, to IND.
The Company previously announced it entered into a purchase agreement with AUG to divest the 800 Series on September 12, 2023.
Third Quarter 2023 Financial Update:
Avalo had $10.2 million in cash and cash equivalents as of September 30, 2023.
The Company raised $46.2 million of net proceeds from equity financings in the nine months ended September 30, 2023.

Avalo Completes Divestiture of AVTX-800 Series

Retrieved on:

Dienstag, Oktober 31, 2023

FDA, Sale, Food, MD, SRD5A3-CDG, Birth, PRV, Purchasing, Rover 800 series, John Avalos, Glycosylation, Asset purchase agreement, AUG, Therapy, Series, Patient, Sales management, Pharmaceutical industry

WAYNE, Pa. and ROCKVILLE, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series) to AUG Therapeutics, LLC (AUG).

Key Points:

WAYNE, Pa. and ROCKVILLE, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series) to AUG Therapeutics, LLC (AUG).
The Company previously announced it entered into a purchase agreement with AUG to divest the 800 Series on September 12, 2023 (the Purchase Agreement).
Additionally, AUG assumed $150,000 of certain liabilities incurred prior to the date of the Purchase Agreement and assumed all costs relating to the 800 Series from the date of the Purchase Agreement.
“We are excited to announce that we have closed the transaction with AUG to divest our 800 Series programs for the treatment of congenital disorders of glycosylation (CDGs).

Avalo Enters into Agreement to Divest AVTX-800 Series

Retrieved on:

Dienstag, September 12, 2023

Purchasing, PRV, John Avalos, Sale, Sales management, MD, Patient, Birth, Asset purchase agreement, SRD5A3-CDG, FDA, Therapy, Glycosylation, Rover 800 series, Food, Pharmaceutical industry, AUG

, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG Therapeutics, LLC (AUG) to sell its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series).

Key Points:

, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG Therapeutics, LLC (AUG) to sell its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series).
Additionally, AUG will assume up to $150,000 of certain liabilities incurred prior to the date of the Purchase Agreement and assume all costs relating to the 800 Series from the date of the Purchase Agreement.
The transaction is expected to close in the fourth quarter of 2023, subject to customary closing conditions, including obtaining certain third-party consents.
“We are excited to announce the transfer of our 800 series programs for the treatment of congenital disorders of glycosylation (CDGs) to AUG.